The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review of products that address major health priorities.

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

Novo Nordisk's 7.2 mg Wegovy injectable aims to enhance chronic weight management in adults with obesity, using an expedited FDA review process. The Phase III STEP UP trial showed semaglutide 7.2 mg's ...

Federal regulators are warning about safety concerns amid the rising popularity of drugs like Ozempic and Wegovy for weight loss. The U.S. Food and Drug Administration is warning consumers that ...

How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Novo Nordisk submitted a higher-dose version of semaglutide (Wegovy) to the FDA for approval as a weight-management treatment ...